SSTR2 and meningioma: The European Organization for Research and Treatment of Cancer (EORTC) is initiating the LUMEN-1 trial (NCT06326190), the first randomized study to compare [177Lu]DOTATATE versus the investigator’s choice (e.g., octreotide, everolimus, bevacizumab, sunitinib, hydroxyurea, or observation) in SSTR2-positive meningiomas.